NASDAQ:BCYC

Bicycle Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy BCYC

*Your capital is at risk

$4.20

-0.1000 (-2.33%)

At Close: Jun 03, 2026

Bicycle Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 65.51. In total, the insiders bought 1.96M and sold 85.81K BCYC shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	65.51
● Buy	1.96M shares
● Sell	85.81K shares
50% Buy Activity Strong Negative Correlation
Buy Signal Medium Confidence Mar 17, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 65.51. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 05, 2026 Sell	Ordinary Shares S-Sale	Young Alethia Chief Financial Officer	C-Suite Officer	2 456 Value: $15.8K
Jan 05, 2026 Sell	Ordinary Shares S-Sale	Young Alethia Chief Financial Officer	C-Suite Officer	1 878 Value: $12.3K
Jan 02, 2026 Buy	American Depositary Shares A-Award	Baker Bros. Advisors Lp	Director	19 000 Value: $126.9K
Jan 02, 2026 Buy	Ordinary Shares A-Award	Swanton Robert Charles Director	Director	3 726 Value: $24.9K
Jan 02, 2026 Buy	Ordinary Shares A-Award	Gutierrez-ramos Jose-carlos Director	Director	9 500 Value: $63.5K
Jan 02, 2026 Buy	Ordinary Shares A-Award	Bourque Janice Director	Director	9 500 Value: $63.5K
Jan 02, 2026 Buy	Ordinary Shares A-Award	Hoppenot Herve Director	Director	3 032 Value: $20.3K
Jan 02, 2026 Buy	Stock Option (right to buy) A-Award	Winter Gregory Paul Director	Director	19 000 Value: $134.5K
Jan 02, 2026 Buy	Ordinary Shares A-Award	Winter Gregory Paul Director	Director	9 500 Value: $63.5K
Jan 02, 2026 Sell	Ordinary Shares S-Sale	Young Alethia Chief Financial Officer	C-Suite Officer	3 289 Value: $22.4K
Jan 02, 2026 Buy	Employee Stock Option (right to buy) A-Award	Young Alethia Chief Financial Officer	C-Suite Officer	100 000 Value: $708.0K
Jan 02, 2026 Buy	Ordinary Shares A-Award	Milnes Alistair Chief Operating Officer	C-Suite Officer	50 000 Value: $334.0K
Jan 02, 2026 Buy	Employee Stock Option (right to buy) A-Award	Hannay Michael Charles Ferguson Chief Prod & Supply Chain Off	Officer	100 000 Value: $708.0K
Jan 02, 2026 Buy	Stock Option (right to buy) A-Award	Dansey Roger D Director	Director	6 065 Value: $42.9K
Jan 02, 2026 Buy	Stock Option (right to buy) A-Award	Riva Alessandro Director	Director	14 761 Value: $104.5K
Jan 02, 2026 Buy	Stock Option (right to buy) A-Award	Sands Stephen H. Director	Director	19 000 Value: $134.5K
Jan 02, 2026 Buy	Employee Stock Option (right to buy) A-Award	Lee Kevin Chief Executive Officer	CEO / President	330 000 Value: $2.34M
Jan 02, 2026 Sell	Ordinary Shares S-Sale	Lee Kevin Chief Executive Officer	CEO / President	10 325 Value: $70.2K
Jan 02, 2026 Sell	Ordinary Shares S-Sale	Skynner Michael Chief Technology Officer	Officer	3 045 Value: $20.7K
Jan 02, 2026 Buy	Ordinary Shares A-Award	Thompson Travis Alvin Chief Accounting Officer	Officer	37 500 Value: $250.5K
Jan 02, 2026 Buy	Employee Stock Option (right to buy) A-Award	Thompson Travis Alvin Chief Accounting Officer	Officer	75 000 Value: $531.0K
Jan 02, 2026 Sell	Ordinary Shares S-Sale	Thompson Travis Alvin Chief Accounting Officer	Officer	1 317 Value: $9K
Jan 02, 2026 Buy	Ordinary Shares A-Award	Skynner Michael Chief Technology Officer	Officer	50 000 Value: $334.0K
Jan 02, 2026 Buy	Ordinary Shares A-Award	Riva Alessandro Director	Director	7 380 Value: $49.3K
Jan 02, 2026 Buy	Ordinary Shares A-Award	Dansey Roger D Director	Director	3 032 Value: $20.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BICYCLE THERAPEUTICS PLC

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial ...

Read Full Profile Here